-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Sutro Biopharma (NASDAQ:STRO) Given New $18.00 Price Target at Piper Sandler
Sutro Biopharma (NASDAQ:STRO) Given New $18.00 Price Target at Piper Sandler
Sutro Biopharma (NASDAQ:STRO – Get Rating) had its target price lifted by Piper Sandler from $16.00 to $18.00 in a research report released on Tuesday morning, The Fly reports. They currently have an overweight rating on the stock.
Separately, HC Wainwright reduced their target price on Sutro Biopharma from $30.00 to $20.00 and set a buy rating on the stock in a research note on Wednesday, November 9th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Sutro Biopharma currently has a consensus rating of Buy and a consensus target price of $19.00.
Get Sutro Biopharma alerts:Sutro Biopharma Price Performance
STRO opened at $7.26 on Tuesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.95 and a current ratio of 5.95. Sutro Biopharma has a 52-week low of $3.33 and a 52-week high of $11.25. The stock has a market capitalization of $417.27 million, a PE ratio of -2.80 and a beta of 0.93. The stock's 50 day moving average price is $7.49 and its 200-day moving average price is $6.47.
Sutro Biopharma (NASDAQ:STRO – Get Rating) last posted its earnings results on Tuesday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.22). Sutro Biopharma had a negative net margin of 175.85% and a negative return on equity of 53.85%. The business had revenue of $25.15 million for the quarter, compared to analysts' expectations of $11.35 million. On average, equities research analysts predict that Sutro Biopharma will post -2.59 EPS for the current year.Institutional Investors Weigh In On Sutro Biopharma
Several hedge funds and other institutional investors have recently added to or reduced their stakes in STRO. State Street Corp grew its stake in Sutro Biopharma by 66.1% in the first quarter. State Street Corp now owns 2,642,486 shares of the company's stock worth $21,721,000 after purchasing an additional 1,051,649 shares during the period. Verition Fund Management LLC purchased a new stake in shares of Sutro Biopharma in the second quarter worth $3,778,000. Point72 Asset Management L.P. purchased a new stake in shares of Sutro Biopharma in the third quarter worth $3,946,000. Parkman Healthcare Partners LLC grew its stake in shares of Sutro Biopharma by 272.5% in the third quarter. Parkman Healthcare Partners LLC now owns 687,335 shares of the company's stock worth $3,815,000 after acquiring an additional 502,817 shares during the last quarter. Finally, Rubric Capital Management LP grew its stake in shares of Sutro Biopharma by 55.6% in the third quarter. Rubric Capital Management LP now owns 1,400,000 shares of the company's stock worth $7,770,000 after acquiring an additional 500,000 shares during the last quarter. 87.64% of the stock is owned by hedge funds and other institutional investors.
About Sutro Biopharma
(Get Rating)
Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.
Featured Articles
- Get a free copy of the StockNews.com research report on Sutro Biopharma (STRO)
- Mobileye Expects $17.5 Billion Future For Its Driver Assist Tech
- Is Salesforce's New Rally The Beginning Of A Big Uptrend?
- Can Lockheed Martin Corporation Hit Another All-Time High in Q1?
- Marathon Digital Holdings, Inc: Slow And Steady Wins The Race
- The WD-40 Company Is Ready To Rebound, But Will It?
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
Sutro Biophma(纳斯达克:Stro-Get评级)据The Fly报道,派珀·桑德勒在周二上午发布的一份研究报告中将其目标价从16.00美元上调至18.00美元。他们目前对该股的评级为增持。
另外,HC Wainwright在11月9日星期三的一份研究报告中将Sutro Biophma的目标价从30.00美元下调至20.00美元,并对该股设定了买入评级。根据MarketBeat的数据,五位研究分析师对该股的评级为买入,Sutro Biophma目前的共识评级为买入,共识目标价为19.00美元。
到达经生物咽警报:Sutro Biopma价格表现
Stro周二开盘报7.26美元。该公司的负债权益比率为0.03,速动比率为5.95,流动比率为5.95。Sutro Biophma的52周低点为3.33美元,52周高位为11.25美元。该股市值为4.1727亿美元,市盈率为-2.80,贝塔系数为0.93。该股的50日移动均线价格为7.49美元,200日移动均线价格为6.47美元。
Sutro Biophma(纳斯达克:Stro-Get Rating)最近一次公布财报是在11月8日(星期二)。该公司公布了该季度每股收益(EPS)(0.37美元),低于(0.15美元)和(0.22美元)的普遍预期。Sutro Biophma的净利润率为负175.85%,净资产回报率为负53.85%。该业务当季营收为2,515万美元,高于分析师预期的1,135万美元。平均而言,股票研究分析师预测,Sutro Biophma本年度每股收益将达到2.59欧元。机构投资者看好Sutro Biophma
几家对冲基金和其他机构投资者最近增持或减持了Stro的股份。道富集团第一季度在Sutro Biophma的持股增加了66.1%。道富银行目前持有该公司2,642,486股股票,价值21,721,000美元,在此期间又购买了1,051,649股。Verition Fund Management LLC在第二季度购买了Sutro Biophma价值3,778,000美元的新股。Point72 Asset Management L.P.在第三季度购买了Sutro Biophma价值3946,000美元的新股。Parkman Healthcare Partners LLC在第三季度增持了Sutro Biophma的股份272.5%。Parkman Healthcare Partners LLC在上个季度额外收购了502,817股后,现在拥有687,335股该公司股票,价值3,815,000美元。最后,Rubric Capital Management LP在第三季度增持了Sutro Biophma的股份55.6%。Rubric Capital Management LP在上个季度额外收购了50万股后,现在拥有140万股该公司的股票,价值77万美元。87.64%的股票由对冲基金和其他机构投资者持有。
关于《经·生物咽》
(获取评级)
Sutro Biophma,Inc.作为临床阶段药物发现、开发和制造公司。它专注于通过集成的无细胞蛋白质合成和位点特异性结合平台XpressCF+创建治疗癌症和自身免疫性疾病的蛋白质疗法。该公司的候选产品包括Stro-001,一种针对多发性骨髓瘤和非霍奇金淋巴瘤患者的抗癌靶点CD74的抗体-药物结合物(ADC),正处于第一阶段临床试验;以及Stro-002,一种针对叶酸受体-α的ADC,正处于第一阶段临床试验。
专题文章
- 免费获取StockNews.com关于Sutro Biophma(Stro)的研究报告
- Mobileye预计其驾驶员辅助技术未来价值175亿美元
- Salesforce的新一轮涨势是大涨趋势的开始吗?
- 洛克希德·马丁公司第一季度能否再创历史新高?
- 马拉松数字控股公司:稳扎稳打赢得比赛
- WD-40公司已经准备好反弹了,但它会吗?
接受《Sutro Biophma Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Sutro Biophma和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧